Therapeutic targeting of Ang-2 has shown broad anti-tumor activity in a number of preclinical solid tumor models, and the addition of anti-Ang-2 treatment to cytotoxic drugs or anti-VEGF treatment has resulted in superior effects over single-agent therapy alone [21, 22]. The gene discussed is VEGFA; the disease is neoplasm.